ALMDT Median Technologies

Median Technologies Appoints Jean-Christophe Montigny as Chief Financial Officer and Member of the Executive Committee

Regulatory News:

Median Technologies (Paris:ALMDT) today announces the appointment of Jean-Christophe Montigny as Chief Financial Officer. He will be a member of Median’s executive committee.

Jean-Christophe Montigny succeeds Bernard Reymann, who is stepping down after more than 8 years with the Company.

“We are very happy that Jean-Christophe Montigny is joining our company. His experience in supporting the growth of companies such as Median as well as in preparing for a listing on the NASDAQ are decisive factors for our company. Jean-Christophe will be key for the next milestones in Median's stock market and financial history, "said Fredrik Brag, CEO and founder of Median Technologies. “We would also like to sincerely thank Bernard Reymann for his daily involvement and for more than 8 years as CFO of Median. Bernard was very active in the development of our company and supported all stages after our IPO in 2011. We warmly wish him the best of luck and success in his new personal endeavors”.

“I am very honored to join Median, a company recognized in the field of artificial intelligence linked to health, and enthusiastic about the idea of being able to support this high-level team in a new expansion, innovation, and value creation cycle for the benefit of patients”, adds Jean-Christophe Montigny.

Jean-Christophe Montigny joins Median Technologies with more than 25 years of management committee experience, in large group subsidiaries and SMEs with high growth potential financed by venture capital and the stock market, in particular on the Euronext Growth market.

Jean-Christophe Montigny was particularly involved in the development and acceleration of international growth, in particular, of Biophytis SA, of which he was the financial director and deputy managing director from 2009 to 2019, and for which he steered the listing on Euronext Growth and the preparation phase for listing on the NASDAQ.

Jean-Christophe holds an engineering degree from Agroparistech and is a graduate of the Paris Institute of Political Studies (Sciences Po, Paris).

Jean-Christophe took up his position on July 12, 2021 as a member of the executive committee of Median and under the direct responsibility of Fredrik Brag, CEO and founder of Median.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on the Euronext Growth market. FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), listed on the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information:

EN
29/07/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Median Technologies

Median Technologies: 1 director

A director at Median Technologies sold 14,000 shares at 3.161EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

Maria Vara
  • Maria Vara

Median Technologies: EUR23.5m capital raise extends runway into Q4 202...

Median Technologies successfully secured a capital raise via ABSA of EUR23.5m in total gross proceeds, priced at EUR1.66 (at ~18% discount to 20-day VWAP). The offering was oversubscribed, surpassing the initial EUR22m target, with 64% backed by existing shareholders, 2% by a public offering in Fra

Maria Vara
  • Maria Vara

Median Technologies: Launch of EUR22m capital increase to unlock EIB f...

Median Technologies has launched a EUR22m capital increase via a public offering of shares with warrants (ABSA), priced at EUR1.66 (at ~18% discount to 20-day VWAP), with 78% of the deal already secured via existing and new investors. The raise aimed to i) meet the drawing conditions of the Tranche

Maria Vara
  • Maria Vara

Median Technologies: EIB loan signed, tied to equity raise and debt re...

Friday post-market, Median announced the final sign of the EIB loan agreement of EUR37.5m, which has been structured in three tranches (EUR19m, EUR8.5m, EUR10m) and with several key conditions being set to access the first one. These include i) a capital increase of at least EUR16m (including issua

Maria Vara
  • Maria Vara

Median Technologies: CE mark filing keep eyonis on track, US launch be...

Yesterday post-market, Median announced that it has submitted the Class IIb CE marking filing for eyonis LCS, just a month after the FDA 510(k) submission, precisely sticking to the company's timeline guidance. Our confidence in a positive outcome remains high, as both submissions are underpinned b

ResearchPool Subscriptions

Get the most out of your insights

Get in touch